PepGen Inc. (PEPG)
NASDAQ: PEPG · Real-Time Price · USD
1.530
-0.070 (-4.38%)
Apr 29, 2025, 4:00 PM EDT - Market closed
Company Description
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States.
Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy.
The company was founded in 2018 and is based in Boston, Massachusetts.
PepGen Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | May 6, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 81 |
| CEO | James McArthur |
Contact Details
Address: 321 Harrison Avenue, 8th Floor Boston, Massachusetts 02118 United States | |
| Phone | 781 797 0979 |
| Website | pepgen.com |
Stock Details
| Ticker Symbol | PEPG |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $12.00 |
| CIK Code | 0001835597 |
| CUSIP Number | 713317105 |
| ISIN Number | US7133171055 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. James G. McArthur Ph.D. | President, Chief Executive Officer, Treasurer, Secretary and Director |
| Noel P. Donnelly M.B.A. | Chief Financial Officer |
| Dr. Michael Gait Ph.D. | Founder and Scientific Advisory Board Member |
| Emiko Bryant | Chief of Staff, Human Resources and Operations |
| David E. Borah C.F.A., M.B.A. | Senior Vice President of IR and Corporate Communications |
| Mary Beth DeLena J.D. | General Counsel and Secretary |
| Dr. Hayley Parker Ph.D. | Senior Vice President of Global Regulatory Affairs |
| Dr. Afsaneh Mohebbi Ph.D. | Senior Vice President of Portfolio and Program Management |
| Dr. Paul D. Streck M.B.A., M.D. | Executive Vice President and Head of Research and Development |
| Kyle Breidenstine CPA, M.B.A. | Vice President of Finance and Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 31, 2025 | 8-K | Current Report |
| Mar 28, 2025 | 8-K | Current Report |
| Mar 4, 2025 | 8-K | Current Report |
| Feb 28, 2025 | SCHEDULE 13G | Filing |
| Feb 24, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 24, 2025 | 8-K | Current Report |
| Feb 24, 2025 | 10-K | Annual Report |